Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Meiji Seika Pharma Licenses Udenafil from Dong-A Pharmaceutical
December 20, 2011
- GSK Applies for Add’l Indication for Botox for Axillary Hyperhidrosis
December 20, 2011
- SMBC Nikko Securities Includes Astellas Pharma in 20 Stocks to Watch in 2012
December 19, 2011
- Takeda Decides not to Commercialize Peginesatide in Japan
December 19, 2011
- Valeant Announces Successful Results from PIII Onychomycosis Study of Efinaconazole
December 19, 2011
- Pfizer Tops Doctor Survey Rankings for Pharmaceutical Company Website Access
December 16, 2011
- Chugai to Set Up Company in Singapore Targeting Antibody Drug Discovery
December 16, 2011
- Sanofi-aventis Appeals to IP High Court Claiming Allegra’s Use Patents
December 16, 2011
- Eisai Receives Approval for Halaven in Canada
December 16, 2011
- Shionogi’s Subsidiary Starts Biomarker Discovery Research in the US
December 16, 2011
- ReproCELL to Commercialize World’s 1st iPS Cell-Derived Hepatocytes in April
December 16, 2011
- Janssen Voluntarily Recalls Risperdal Tablet 1 mg
December 15, 2011
- Ibandronate Shows Non-inferiority to Risedronate: Chugai, Taisho
December 15, 2011
- Over 60% of Doctors Support Exclusion of Anticancer Drugs from Current Relief System: CareNet
December 15, 2011
- Ono Enters into Joint Research Agreement with US Company to Discover Antagonists for GPCR Target
December 14, 2011
- MTPC to Seek Strategic Alliance to Expand Generics Business: President Tsuchiya
December 14, 2011
- GSK Submits NDA for Pazopanib in Japan
December 14, 2011
- MTPC to Focus on Development of Global Human Resources
December 14, 2011
- Eisai Files Application for New Aricept Dry Syrup Formulation
December 14, 2011
- SGN-35 for Treatment-naïve Lymphoma to Progress to PIII: Takeda
December 14, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…